351 related articles for article (PubMed ID: 27140797)
1. A thorough QT/QTc study of the effect of fasiglifam, a GPR40 agonist, on cardiac repolarization in healthy adults.
Lee RD; Nudurupati S; Marcinak J; Viswanathan P
Clin Pharmacol Drug Dev; 2015; 4(3):175-83. PubMed ID: 27140797
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
3. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
4. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study.
Pinto R; l'Hostis P; Patat A; Homery MC; Falcão A; Nunes T; Rocha JF; Soares-da-Silva P
Clin Pharmacol Drug Dev; 2015 Nov; 4(6):454-62. PubMed ID: 27137718
[TBL] [Abstract][Full Text] [Related]
6. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
Zhang W; Smulders R; Abeyratne A; Dietz A; Krauwinkel W; Kadokura T; Keirns J
Clin Ther; 2013 Aug; 35(8):1150-1161.e3. PubMed ID: 23910665
[TBL] [Abstract][Full Text] [Related]
7. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
8. The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.
Ring A; Brand T; Macha S; Breithaupt-Groegler K; Simons G; Walter B; Woerle HJ; Broedl UC
Cardiovasc Diabetol; 2013 Apr; 12():70. PubMed ID: 23617452
[TBL] [Abstract][Full Text] [Related]
9. Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals.
Hoch M; Darpo B; Brossard P; Zhou M; Stoltz R; Dingemanse J
Basic Clin Pharmacol Toxicol; 2015 May; 116(5):429-37. PubMed ID: 25287214
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
[TBL] [Abstract][Full Text] [Related]
11. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
[TBL] [Abstract][Full Text] [Related]
12. A Thorough QT Study to Evaluate the Effects of a Supratherapeutic Dose of Sertraline on Cardiac Repolarization in Healthy Subjects.
Abbas R; Riley S; LaBadie RR; Bachinsky M; Chappell PB; Crownover PH; Damle B
Clin Pharmacol Drug Dev; 2020 Apr; 9(3):307-320. PubMed ID: 31777203
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers.
Cassella JV; Spyker DA; Yeung PP
Int J Clin Pharmacol Ther; 2015 Nov; 53(11):963-71. PubMed ID: 26501204
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effect of ruxolitinib on cardiac repolarization: A thorough QT study.
Punwani N; Yeleswaram S; Chen X; Bowman J; Soloviev M; Williams W
Clin Pharmacol Drug Dev; 2014 May; 3(3):207-14. PubMed ID: 27128611
[TBL] [Abstract][Full Text] [Related]
15. A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.
Tatosian DA; Cardillo Marricco N; Glasgow XS; DeGroot B; Dunnington K; George L; Gendrano IN; Johnson-Levonas AO; Swearingen D; Kauh E
Clin Pharmacol Drug Dev; 2016 Sep; 5(5):383-92. PubMed ID: 27627194
[TBL] [Abstract][Full Text] [Related]
16. Lack of an Effect of Supratherapeutic Dose of Venlafaxine on Cardiac Repolarization in Healthy Subjects.
Abbas R; Riley S; Nepal S; Bachinsky M; Lee KC; Chappell PB; Damle B
Clin Pharmacol Drug Dev; 2022 Jan; 11(1):100-111. PubMed ID: 34242472
[TBL] [Abstract][Full Text] [Related]
17. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
Peng XV; Marcinak JF; Raanan MG; Cao C
Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the effect of mericitabine at projected therapeutic and supratherapeutic doses on cardiac repolarization in healthy subjects: A thorough QT/QTc study.
Chen YC; Haznedar J; Kulkarni R; Vistuer C; Washington C; Liu M; Smith P
Clin Pharmacol Drug Dev; 2014 May; 3(3):179-86. PubMed ID: 27128607
[TBL] [Abstract][Full Text] [Related]
19. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
[TBL] [Abstract][Full Text] [Related]
20. Deferasirox does not induce QT/QTc-prolongation in healthy subjects.
Sechaud R; Dumortier T; Balez S
Int J Clin Pharmacol Ther; 2009 May; 47(5):321-7. PubMed ID: 19473594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
